en · de · es
aod-9604-notes.peptides1004.com › Faq › Identity And Molecular Context — Explained

Identity And Molecular Context — Explained

By Editorial Desk · published 2026-02-23 · last reviewed 2026-03-15 · Faq

This is a working overview of mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-03-15 and is reviewed periodically as new material appears.

Identity and Molecular Context

Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.

Identity And Research Background

AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.

AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.

AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.

Aod-9604 at a glance

PropertyValueNotes
Molecular classSynthetic peptideDerived from a fragment of human growth hormone
Sequence basishGH residues 176-191Commonly described as a 16-amino-acid fragment
AppearanceWhite to off-white powderTypical for lyophilized research peptides
SolubilitySoluble in water or aqueous bufferExact solubility depends on pH and purity
Common synonymsAOD9604; hGH 176-191Spelling and punctuation vary across sources

Identity and Research Context

Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.

Related pages on this site

Research and Regulatory Context

Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.

AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Regulatory and Analytical Context

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

Background from the literature

Pyruvate formate-lyase activating enzyme (PFL-AE) catalyzes the activation of PFL, a central enzyme in anaerobic glucose metabolism in microbes. Benzylsuccinate synthase (BSS) is a central enzyme in anaerobic toluene catabolism.

The densities of the two phases must also be sufficiently different so that the phases will move past each other in the column. Many DCCC solvent systems contain both chloroform and water. The solvent system used in the seminal publication was made from chloroform, acetic acid, and aqueous 0.1 M hydrochloric acid. Many subsequent solvents systems were made with chloroform, methanol, and water which is sometimes represented as a ChMWat solvent system. Solvent systems formulated with ''n''-butanol, water and a modifier such as acetic acid, pyridine or n-propanol have also enjoyed some success in DCCC. In some cases, non-aqueous biphasic solvent systems such as acetonitrile and methanol have been utilized. The main difference between DCCC and other types of countercurrent chromatography techniques is that there is no vigorous mixing of phases to enhance the mass transfer of compounds that allows them to distribute between the two phases. In 1951 Kies and Davis described an apparatus similar to the DCCC. They created a series of open tubes that were arranged in a cascade to either drip a more dense phase through a less dense stationary phase or, conversely, a less dense phase could be introduced into the bottom of the tube to dribble through the more dense phase. In 1954, a fractionation column was introduced by Kepes the resembled a CCC column divided into chambers with perforated plastic disks. Similar DCCC-type instruments have been created by A. E. Kostanyan and collaborators which employ vertical columns that are divided into partitions with porous disks.

== Overview of technique == Freeze branding can permanently alter the color of a mammal's coat, leaving the branded area white for the rest of its life. This is ultimately caused by the formation of ice crystals within melanocytes, the cells that normally coat the hair shaft with pigment as the growth root pushes the hair out of the follicle. This ice physically disrupts the microtubules along which melanin granules are transported from within the cell to its membrane, where they normally undergo exocytosis. That cellular machinery is permanently damaged after the cells thaw, preventing the surviving melanocytes from ever again secreting melanin. Most melanocytes rapidly fall into apoptosis and fail to regenerate. There are two types of freeze branding, one requiring a longer application of the brand than the other. Pigmented animals may be branded more quickly than pale animals because dark coats require only the hair follicles' pigmentation apparatus to be destroyed. This causes the branded skin to regrow hair to which no pigment has been applied as it leaves the hair sheath, rendering the shaft microscopically clear and macroscopically white. Pale animals require a longer branding time to kill the deepest part of the follicle, which secretes the hair shaft itself. This prevents any hair regrowth, leaving a bald patch of skin generally darker than the animal's coat. Freeze branding thereby ensures high contrast even on white-coated animals. The difference in branding time between the two methods is minimal, often separated by only a few seconds.

Using alpha particles from radium to strike air, Rutherford detected scintillation on a zinc sulfide screen at a distance, up to 28 cm, well beyond the distance of alpha-particle range of travel but instead corresponding to the range of travel of hydrogen atoms. By 1920 he concluded that these hydrogen nuclei were a constituent part of the nitrogen nucleus. This result has been described as the discovery of protons. When Rutherford described his results at the British Association for the Advancement of Science August 1920 he was asked by Oliver Lodge for a new name for the positive hydrogen nucleus to avoid confusion with the neutral hydrogen atom. Rutherford initially suggested both proton (the neuter singular of the Greek word for "first", πρῶτον) and prouton (after Prout). Rutherford later reported that the meeting had accepted his suggestion that the hydrogen nucleus be named the "proton", following Prout's word "protyle". The first use of the word "proton" in the scientific literature appeared in 1920. Rutherford initially assumed that the alpha particle merely knocked a proton out of nitrogen, turning it into carbon. Patrick Blackett's cloud chamber images in 1925 demonstrated that the alpha particle was absorbed. If the alpha particle were not absorbed, then three charged particles, a negatively charged carbon, a proton, and an alpha particle, would be expected. The three charged particles would create three tracks in the cloud chamber, but only two tracks in the cloud chamber were observed. Blackett proposed that the alpha particle is absorbed by the nitrogen atom.

Although they live and work in Hong Kong, these workers are not treated as ordinary residents and do not have the right of abode in the territory. The Joint Declaration guarantees the Basic Law of Hong Kong for 50 years after the handover. According to legal scholar Albert Chen, the Basic Law does not have an expiry date and is, unless amended, of continuing validity. In response to large-scale protests in 2019 and 2020, the Standing Committee of the National People's Congress passed the controversial Hong Kong national security law. The law criminalises secession, subversion, terrorism and collusion with foreign elements and establishes the Office for Safeguarding National Security of the CPG in the HKSAR, an investigative office under Central People's Government authority immune from HKSAR jurisdiction. Some of the aforementioned acts were previously considered protected speech under Hong Kong law. The United Kingdom considers the law to be a serious violation of the Joint Declaration. In October 2020, the Hong Kong Police arrested seven pro-democracy politicians over tussles with pro-Beijing politicians in the Legislative Council in May. They were charged with contempt and with interfering with council members, while none of the pro-Beijing lawmakers were detained. Annual commemorations of the 1989 Tiananmen Square protests and massacre were also cancelled amidst fears of violating the national security law.

Sources: en.wikipedia.org

Further detail

== See also == Baby Friendly Hospital Initiative Breastfeeding promotion Breastfeeding contraindications Haberman Feeder Infant formula International Code of Marketing of Breast-milk Substitutes List of bottle types, brands and companies

The result of this extensive procedure was still not a pure protein, but it produced a limited number of bands by SDS-PAGE, and one band of 46 kilodaltons was found to correlate in intensity with the enzymatic activity. This band was cut from the gel and digested with trypsin, and peptides from it were separated from one another by reverse phase high performance liquid chromatography. The resulting fragments were then microsequenced by an automated Edman degradation. Three corresponded to vimentin, an intermediate filament protein of 56 kDa believed to be a contaminant, and the other two matched the cDNA clone subsequently identified as NAPE-PLD. Once this clue had been obtained, the identification could be confirmed by a less onerous procedure: Overexpression of the putative NAPE-PLD cDNA in COS-7 cells yielded a strong NAPE-PLD enzymatic activity, whose characteristics were shown to be similar to those of the original heart extract.

In 1912, Knoxvillians replaced their mayor-alderman form of government with a commissioner form of government that consisted of five commissioners elected at-large, and a mayor chosen from among the five. Following the 1917 annexations, the city began to struggle as it extended services to the newly annexed areas, and it became clear the new government was ineffective at dealing with the city's financial issues. In 1923, the city voted to replace the commissioners with a city manager-council form of government, which involved the election of a city council, who would then hire a city manager to oversee the city's business affairs. The first city manager hired by Knoxville was Louis Brownlow, the successful city manager of Petersburg, Virginia, and a cousin of Parson Brownlow. When Brownlow arrived in Knoxville, he was horrified by the city's condition, later writing that he found "something new and more disturbing" every day. There were no paved roads connecting Knoxville with other major cities. The lone operable tank of the city's waterworks was full of cracks that Knoxvillians had been lazily plugging with gunny sacks. The city hospital was unable to buy drugs, as it was deeply in debt, and its credit had been cut off. City Hall, then located on Market Square, was filthy, noisy and disorganized.

Abdomen and rectum Cardiovascular (heart and blood vessels) General appearance of the patient and specific indicators of disease (nutritional status, presence of jaundice, pallor or clubbing) Genitalia (and pregnancy if the patient is or could be pregnant) Head, eye, ear, nose, and throat (HEENT) Musculoskeletal (including spine and extremities) Neurological (consciousness, awareness, brain, vision, cranial nerves, spinal cord and peripheral nerves) Psychiatric (orientation, mental state, mood, evidence of abnormal perception or thought). Respiratory (large airways and lungs) Skin Vital signs including height, weight, body temperature, blood pressure, pulse, respiration rate, and hemoglobin oxygen saturation It is to likely focus on areas of interest highlighted in the medical history and may not include everything listed above. The treatment plan may include ordering additional medical laboratory tests and medical imaging studies, starting therapy, referral to a specialist, or watchful observation. A follow-up may be advised. Depending upon the health insurance plan and the managed care system, various forms of "utilization review", such as prior authorization of tests, may place barriers on accessing expensive services. The medical decision-making (MDM) process includes the analysis and synthesis of all the above data to come up with a list of possible diagnoses (the differential diagnoses), along with an idea of what needs to be done to obtain a definitive diagnosis that would explain the patient's problem.

== Medical uses == Brief reactive psychosis and hypochondriasis-senestopathic syndrome Vegetative dysfunction and vegetative lability Alcohol withdrawal syndrome Temporal lobe epilepsy and myoclonic epilepsy (used only occasionally as better options exist) Hyperkinesia and tics Muscle spasticity Usually, a course of treatment with phenazepam should not normally exceed 2 weeks (in some cases therapy may be prolonged for up to 2 months) due to the risk of drug abuse and dependence. To prevent withdrawal syndrome, it is necessary to reduce the dose gradually.

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 the same as human growth hormone?

No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.

What is the exact length of AOD-9604?

It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.

Does AOD-9604 occur naturally?

It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.

Is AOD-9604 the same as human growth hormone?

No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.

Network